Isis Pharmaceuticals preclinical data

ISIS 388626 produced a dose-dependent reduction in kidney levels of sodium-glucose cotransporter 2 (SGLT2), with a >75% reduction at the highest dose and a significant increase (>100-fold) in glucose...